A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
about
Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapiesOne year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trGastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.Regulation of energy balance and body weight by the brain: a distributed system prone to disruption.Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.Incretin therapy--present and future.The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutideImpact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysisThe fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.Therapy in the early stage: incretins.Controlled release of liraglutide using thermogelling polymers in treatment of diabetesLiraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot studyComparative effectiveness of liraglutide in the treatment of type 2 diabetes.Role of the glucagon-like-peptide-1 receptor in the control of energy balance.Liraglutide for weight management: a critical review of the evidence.Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.Novel GLP-1 receptor agonists for diabetes.Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.GLP-1R activation for the treatment of stroke: updating and future perspectives.Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy.Liraglutide: an injectable option for the management of obesity.Liraglutide for Type 2 diabetes and obesity: a 2015 update.Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists.Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.The Effects of a GLP-1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model.Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide.Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus.Incretin-based therapies for type 2 diabetes: a nurse's perspective.Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour.Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literatureLiraglutide withdrawal rates: ‘real world’ practice
P2860
Q33607749-3CD0E436-244A-425D-A516-354CD6C2D833Q33734024-4E0B8D9B-DCDA-4E27-9237-EB1586FFD855Q34627077-B736CC44-B697-4D8E-A586-2D032592547CQ34893192-DF96E8D6-3F54-4599-9CE7-905F09079E87Q34915090-6B205F80-D791-47F3-B0CE-7E97FA2DF50CQ35569563-EFA2E83A-17B9-49E0-BB71-46C23CE3D979Q35654002-F3036156-4BAC-45C5-AF5E-01A5B85A0392Q35690970-76C677FC-5A69-4E0D-98D8-8019D72BD184Q35760283-053D885B-E507-4B11-84E0-28A1AE2CE7DDQ36368988-1C3C1AC1-150D-4C46-A6BD-741C3EBA75CFQ36520655-1FBAF1E2-7170-4C1C-A77D-B56BEBDBC697Q36629515-93DB25F7-A0DE-4C8D-A54D-1833AA5E9187Q36783865-9FAF39E2-D026-43F6-BC2F-FB0BCD3C05F1Q37181542-DA06E5EB-4948-4DEE-BA0B-3F303D1E907EQ37470522-E399018D-A449-408C-8D3B-9E0502A41053Q37627628-D4F2083A-910E-451E-A8FD-2A8E37AE055FQ37659673-F3A21F73-CE5D-493E-8A82-3E9D194225AAQ37708356-C5B7653F-E3EB-4F46-8669-AF1EE6744DF1Q37711170-9C9114B1-01D4-405C-9E4E-F6A18C8CBC06Q37825946-D8533834-D57D-4EAD-8831-27BC026E2DE1Q37900626-B319C3EE-56D6-43B0-B7CD-FABDB84219A2Q37960149-E35DBDA5-7852-49BC-8FA1-5D4C0F6CE84AQ37992255-5AAC1FA1-47DF-43AA-8BD9-55B6B74B4D4BQ38207948-F9FF14F7-0DA9-459A-ACA1-EE997DB6C11AQ38219485-DEE0A515-19EF-4FCD-AE7A-DB307BC32484Q38488897-9FFEE154-E661-4551-8E86-470398D6C6C4Q38536672-43F2015A-76AF-4046-A32E-AB94CE70DB72Q38634679-C6F86413-A299-41E0-B9BB-066BADA06D6BQ39199887-04E78C1C-F37F-401E-905D-92D346B34798Q39988607-B9F332D2-9C3E-4D56-864F-8EF761B100CEQ40529883-D7682817-B60F-42A6-A6D4-17EBEDCD8265Q40678970-4CBA811D-527F-42B6-994A-AC0650F318CFQ41184651-D3746408-C2B4-46AD-AC00-4A1CFB76701EQ42130324-48C2D231-80DC-4324-8258-23B989F520B8Q42578569-0080A2F6-51BE-4292-851E-2BE2792D1396Q42748385-1C5648CD-2C94-4327-A002-918D57470D98Q48670439-C833DF04-C56B-45EA-A257-87DB48A2EF98Q51741479-B714B5B7-BB24-40D5-A040-108C7CF398F0Q57406244-2C943D6F-D608-4F5E-84BB-546764AE070DQ57700755-CBC62030-EE06-4AA9-8C84-3F04BF2A02A4
P2860
A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@ast
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@en
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@nl
type
label
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@ast
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@en
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@nl
prefLabel
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@ast
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@en
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@nl
P1476
A review of efficacy and safet ...... t of type 2 diabetes mellitus.
@en
P304
P356
10.1016/J.CLINTHERA.2009.11.034
P577
2009-11-01T00:00:00Z